ALEXANDRIA, Va., June 25 -- United States Patent no. 12,338,280, issued on June 24, was assigned to UNIVERSITATSKLINIKUM REGENSBURG (Regensburg, Germany).
"Antibodies targeting IL3" was invented by Matthias Mack (Regensburg, Germany).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to antibodies and antibody fragment that are specific for IL3, as well as nucleic acids encoding such antibodies and pharmaceutical compositions comprising such antibodies. The antibodies of the present invention are able to block IL-3 activity in target cells and are useful for the prevention and treatment of diseases or malfunctions which are associated with elevated levels of IL3, such as inflammator...